![](/img/cover-not-exists.png)
A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
Brana, I, Berger, R, Golan, T, Haluska, P, Edenfield, J, Fiorica, J, Stephenson, J, Martin, L P, Westin, S, Hanjani, P, Jones, M B, Almhanna, K, Wenham, R M, Sullivan, D M, Dalton, W S, Gunchenko, A,Volume:
111
Language:
english
Journal:
British Journal of Cancer
DOI:
10.1038/bjc.2014.497
Date:
November, 2014
File:
PDF, 460 KB
english, 2014